Great Point Partners’s Emergent Biosolutions EBS Stock Holding History

Great Point Partners’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-102,791	Closed	-$2.96M	–	35
2015 Q1	$2.96M	Sell	102,791 -147,209	-59%	-$4.22M	1.3%	22
2014 Q4	$6.81M	Sell	250,000 -40,000	-14%	-$953K	3.28%	11
2014 Q3	$6.18M	Buy	+290,000	New	+$6.64M	2.65%	18

Other funds holding EBS

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

FMA

Fiduciary Management Associates Chicago, Illinois $1.53B AUM 4.47% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Great Point Partners's EBS Position: Q2 2015 in Review

Great Point Partners sold out of Emergent Biosolutions (EBS) in Q2 2015, closing a stake of 102,791 shares — an estimated $2.96M sold.

Great Point Partners first reported a position in EBS in Q3 2014 and held it in 3 quarters. The position peaked at $6.81M in Q4 2014. 184 funds tracked by Wall St. Rank hold EBS as of Q2 2015.

Great Point Partners reported no remaining Emergent Biosolutions position as of Q2 2015 after selling out during the quarter.
Great Point Partners sold 102,791 Emergent Biosolutions shares in Q2 2015, an estimated $2.96M.
Great Point Partners first reported a position in Emergent Biosolutions in Q3 2014 and held it in 3 quarters.
Great Point Partners's Emergent Biosolutions position peaked at $6.81M in Q4 2014.
184 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2015.

Based on Great Point Partners's 13F filing for Q2 2015, filed 14 Aug 2015.